EcoDrugPlus

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSPLAG00000009546
Gene Symbol: CYP19A1
4 Cross references
244 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSPLAG00000020416
Gene Symbol: CYP3A65
1 Cross references
145 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSPLAG00000007708
Gene Symbol: LOC106952962
3 Cross references
188 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSPLAG00000018971
Gene Symbol: LOC106964957
3 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSPLAG00000008423
Gene Symbol: LOC106951004
3 Cross references
214 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSPLAG00000011729
Gene Symbol: DGAT1
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSPLAG00000009865
Gene Symbol: LOC106946045
3 Cross references
190 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSPLAG00000020410
Gene Symbol: DHODH
3 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSPLAG00000023274
Gene Symbol: DPYD
3 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSPLAG00000013923
Gene Symbol: DDR2
3 Cross references
204 Possible Orthologues:

Discoidin Domain-Containing Receptor 2-Like

Ensembl ID : ENSPLAG00000008855
Gene Symbol: LOC106946471
2 Cross references
190 Possible Orthologues:

Disintegrin And Metalloproteinase Domain-Containing Protein 17-Like

Ensembl ID : ENSPLAG00000015582
Gene Symbol: LOC106954181
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).